📊 EKSO Key Takeaways
Is EKSO a Good Investment? Thesis Analysis
Ekso Bionics faces severe operational challenges with negative operating and net margins exceeding -100%, deteriorating revenue (-28.6% YoY), and massive cash burn (-$12M FCF) that threatens sustainability. Despite maintaining adequate liquidity ratios, the company's inability to generate positive operating cash flow, combined with persistent losses and negative ROE/ROA, indicates fundamental business model distress requiring immediate operational restructuring.
Why Buy EKSO? Key Strengths
- Solid gross margin of 53.5% demonstrates pricing power and product viability at unit economics level
- Current ratio of 1.63x and quick ratio of 1.07x provide adequate short-term liquidity cushion
- Conservative leverage with debt-to-equity of 0.22x limits financial distress risk in near term
EKSO Investment Risks to Consider
- Revenue contraction of 28.6% YoY indicates severe demand weakness or market share loss requiring immediate strategic intervention
- Operating cash flow of -$11.8M with negative FCF margin of -93.7% at current burn rate exhausts $1.2M cash reserves in 1-2 months without financing
- Deeply negative profitability metrics (operating margin -104.1%, net margin -91.4%, ROE -129.6%) signal unsustainable business operations and value destruction
- Heavy net losses of -$11.7M on only $12.8M revenue indicates severe cost structure misalignment and operational inefficiency
Key Metrics to Watch
- Quarterly revenue trend - stabilization or continued decline signals market viability
- Operating cash flow - path to positive OCF is critical for survival without continuous financing
- Cash burn rate and runway - days of cash available given current cash consumption patterns
- Gross margin sustainability - any decline below 50% would further deteriorate fundamental value
- Product adoption and pipeline - evidence of new customer wins to support revenue recovery
EKSO Financial Metrics
💡 AI Analyst Insight
EKSO BIONICS HOLDINGS, INC. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
EKSO Profitability Ratios
EKSO vs Industrial Sector
How EKSO BIONICS HOLDINGS, INC. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EKSO Overvalued or Undervalued?
Based on fundamental analysis, EKSO BIONICS HOLDINGS, INC. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EKSO Balance Sheet & Liquidity
EKSO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: EKSO BIONICS HOLDINGS, INC.'s revenue has grown significantly by 59% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.43 indicates the company is currently unprofitable.
EKSO Growth Metrics (YoY)
EKSO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.1M | -$1.4M | $-0.54 |
| Q2 2025 | $2.1M | -$2.4M | $-1.24 |
| Q1 2025 | $3.4M | -$2.9M | $-0.12 |
| Q3 2024 | $4.1M | -$2.1M | $-0.10 |
| Q2 2024 | $4.7M | -$2.4M | $-0.13 |
| Q1 2024 | $3.8M | -$3.4M | $-0.20 |
| Q3 2023 | $3.3M | -$3.0M | $-0.24 |
| Q2 2023 | $3.5M | -$3.0M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EKSO Capital Allocation
EKSO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for EKSO BIONICS HOLDINGS, INC. (CIK: 0001549084)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EKSO
What is the AI rating for EKSO?
EKSO BIONICS HOLDINGS, INC. (EKSO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EKSO's key strengths?
Claude: Solid gross margin of 53.5% demonstrates pricing power and product viability at unit economics level. Current ratio of 1.63x and quick ratio of 1.07x provide adequate short-term liquidity cushion.
What are the risks of investing in EKSO?
Claude: Revenue contraction of 28.6% YoY indicates severe demand weakness or market share loss requiring immediate strategic intervention. Operating cash flow of -$11.8M with negative FCF margin of -93.7% at current burn rate exhausts $1.2M cash reserves in 1-2 months without financing.
What is EKSO's revenue and growth?
EKSO BIONICS HOLDINGS, INC. reported revenue of $12.8M.
Does EKSO pay dividends?
EKSO BIONICS HOLDINGS, INC. does not currently pay dividends.
Where can I find EKSO SEC filings?
Official SEC filings for EKSO BIONICS HOLDINGS, INC. (CIK: 0001549084) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EKSO's EPS?
EKSO BIONICS HOLDINGS, INC. has a diluted EPS of $-4.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EKSO a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, EKSO BIONICS HOLDINGS, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EKSO stock overvalued or undervalued?
Valuation metrics for EKSO: ROE of -129.6% (sector avg: 15%), net margin of -91.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy EKSO stock in 2026?
Our dual AI analysis gives EKSO BIONICS HOLDINGS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EKSO's free cash flow?
EKSO BIONICS HOLDINGS, INC.'s operating cash flow is $-11.8M, with capital expenditures of $188.0K. FCF margin is -93.7%.
How does EKSO compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -91.4% (avg: 10%), ROE -129.6% (avg: 15%), current ratio 1.63 (avg: 1.8).